✕
Login
Register
EN
Translate page
EN
English
ES
Español
FR
Français
DE
Deutsch
ZH
中文
AR
العربية
PT
Português
RU
Русский
JA
日本語
KO
한국어
HI
हिन्दी
IT
Italiano
Back to News
Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Muscular Atrophy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000
Benzinga Newsdesk
www.benzinga.com
Neutral 89.9%
Neg 0%
Neu 89.9%
Pos 0%
- Conference Call
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment